Follow-up of hereditary endometrial carcinoma caused by MLH3 gene mutation: a case report

Changlin Zhang, Jiaying Ye, Qiaqia Li, Jijie Zhan, Yang Dong, Jundong Li, Li Tian, Ting WanFrontiers in Oncology 2025 · DOI

TL;DR

This case report identifies a rare germline mutation in the MLH3 gene as a potential "low-risk" driver for hereditary endometrial cancer. By tracking a mother and daughter who both developed the disease at relatively young ages, researchers suggest that MLH3 may work synergistically with other genetic variants to increase tumor susceptibility, even when standard "high-risk" markers are absent.

What Problem Does This Paper Address?

Endometrial cancer (EC) is the sixth most common cancer in women globally. While most cases are sporadic, about 5% are linked to hereditary conditions, most notably Lynch syndrome. Traditionally, Lynch syndrome is diagnosed by looking for mutations in four "major" mismatch repair (MMR) genes: MLH1, MSH2, MSH6, and PMS2.

However, many families exhibit clear hereditary patterns of cancer but test negative for mutations in these four genes. This creates a diagnostic gap. This paper explores whether MLH3—a "newer" and less-studied member of the MMR family—could be the missing link in these "Lynch-like" cases. The authors investigate how MLH3 mutations contribute to cancer development and whether they act alone or in concert with other genetic factors.

Methods

The researchers conducted a longitudinal clinical study of two related patients: a 50-year-old mother and her 30-year-old daughter. Their approach combined:

  • Clinical Diagnostics: Utilizing ultrasound, MRI, PET-CT, and histopathology (including immunohistochemistry for markers like ER, PR, and CA125) to stage and monitor the tumors.
  • Genetic Sequencing: Both patients underwent germline and somatic genetic testing using Next-Generation Sequencing (NGS) to identify mutations across a broad panel of cancer-susceptibility genes.
  • Bioinformatics Analysis: The team used protein function prediction tools—specifically SIFT, Polyphen-2, and Mutation Taster—to evaluate whether the identified mutations were likely to be "harmless" or "deleterious" to protein function.

Datasets

As a clinical case report, the primary "dataset" consists of the unique medical histories and genetic profiles of the two patients. To contextualize their findings, the authors referenced:

  • The Database of Genomic Variation and Phenotype in Humans (Ensembl Resource): Used to compare the MLH3 mutation (located at the 14q24.3 locus) with known clinical outcomes in other patients.
  • The Human Protein Atlas: Used to assess the impact of MLH3 on the prognosis of endometrial cancer.

Key Insights and Ideas

  • The "Low-Risk" Factor: The authors propose that MLH3 is a low-penetrance susceptibility gene. Unlike the "major" MMR genes that almost guarantee a high risk of cancer, MLH3 mutations might only slightly nudge the needle, requiring other factors to trigger malignancy.
  • Microsatellite Stability (MSS): Interestingly, the tumors in this study were microsatellite stable. Usually, MMR defects lead to microsatellite instability (MSI). This suggests that MLH3 might contribute to cancer through alternative pathways or that its role in the MMR complex is partially redundant, masked by other proteins until a "second hit" occurs.
  • Genetic Synergy (Epistasis): Both patients carried mutations in CHEK2 and NBN alongside MLH3. The authors suggest a "multi-hit" model where these mutations work together (synergy) to cross the threshold into carcinogenesis, explaining why the daughter developed cancer at the unusually young age of 30.
  • Broadening the Screen: The study argues for expanding genetic screening for endometrial cancer beyond the standard Lynch syndrome panel to include "minor" MMR genes like MLH3.

Key Results

  • Clinical Success: Both the mother (Stage IIIA) and daughter (Stage IIIC2) achieved complete remission. The mother was treated with a combination of surgery and Abraxane/Carboplatin, while the daughter received surgery, Paclitaxel/Carboplatin, and radiotherapy.
  • Shared Germline Profile: Genetic testing revealed three key shared germline mutations:
  • MLH3 c.3241G>C (p.Asp1081His): Identified as a deleterious mutation affecting DNA repair.
  • CHEK2 c.613A>T (p.Thr205Ser): Linked to DNA double-strand break repair.
  • NBN c.1023C>G (p.Ser341Arg): Involved in cell cycle regulation.
  • Somatic Landscape: The daughter’s tumor also showed significant somatic mutations in PTEN and PIK3R1, which are classic drivers of endometrial cancer, likely acting as the final triggers in a genetically primed environment.

Limitations and Future Work

The primary limitation is the sample size; as a case report of a single family, the findings cannot be generalized to the entire population without larger cohort studies. Additionally, while bioinformatics tools suggest the MLH3 mutation is deleterious, functional laboratory assays (e.g., in vitro repair assays) were not performed to prove exactly how the mutation disrupts the MMR process.

Future work should focus on large-scale genomic studies to quantify the exact relative risk associated with MLH3 variants and to map the specific "synergistic" partners (like CHEK2 or NBN) that turn a low-risk mutation into a high-risk clinical scenario.

Summary updated

Abstract

This case identifies germline heterozygous mutations in two patients, suggesting a potential role for <i>MLH3</i> in endometrial carcinogenesis, which may act as a low-risk factor to increase the risk of tumor susceptibility and does not rule out the possibility of synergistic increases in pathogenicity with other genes.
BibTeX
@inproceedings{zhang2025follow,
  author = {Changlin Zhang and Jiaying Ye and Qiaqia Li and Jijie Zhan and Yang Dong and Jundong Li and Li Tian and Ting Wan},
  title = {{Follow-up of hereditary endometrial carcinoma caused by MLH3 gene mutation: a case report}},
  booktitle = {Frontiers in Oncology},
  year = {2025},
  doi = {10.3389/fonc.2025.1532908},
}
Figure